Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery... Show more
The Aroon Indicator for CZMWF entered a downward trend on September 02, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 204 similar instances where the Aroon Indicator formed such a pattern. In of the 204 cases the stock moved lower. This puts the odds of a downward move at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CZMWF's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 04, 2025. You may want to consider a long position or call options on CZMWF as a result. In of 61 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CZMWF just turned positive on August 18, 2025. Looking at past instances where CZMWF's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .
CZMWF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.827) is normal, around the industry mean (11.022). P/E Ratio (25.338) is within average values for comparable stocks, (59.426). Projected Growth (PEG Ratio) (1.180) is also within normal values, averaging (1.749). Dividend Yield (0.013) settles around the average of (0.016) among similar stocks. P/S Ratio (1.740) is also within normal values, averaging (12.728).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CZMWF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CZMWF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Industry PharmaceuticalsOther
A.I.dvisor tells us that CZMWF and CZMWY have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CZMWF and CZMWY's prices will move in lockstep.
Ticker / NAME | Correlation To CZMWF | 1D Price Change % | ||
---|---|---|---|---|
CZMWF | 100% | N/A | ||
CZMWY - CZMWF | 23% Poorly correlated | -0.47% | ||
SMMNY - CZMWF | 20% Poorly correlated | +0.80% | ||
FONR - CZMWF | 20% Poorly correlated | -0.32% | ||
CLPBY - CZMWF | 17% Poorly correlated | +2.59% | ||
CLPBF - CZMWF | 12% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To CZMWF | 1D Price Change % |
---|---|---|
CZMWF | 100% | N/A |
Pharmaceuticals category (386 stocks) | 3% Poorly correlated | +1.70% |
Pharmaceuticals: Other category (103 stocks) | 1% Poorly correlated | +0.58% |